Orion Secures FDA Approval for Proprietary Dog Anxiety Drug Tessie®, Zoetis to Lead US Sales
OEC sits 73% above its 52-week low of $4.345.
Summary
Orion Animal Health has received US FDA approval for Tessie® (tasipimidine oral solution), a proprietary molecule for treating noise aversion and separation anxiety in dogs. This significant regulatory milestone provides a new potential revenue stream for Orion, especially as it follows the company's recent Q1 2026 report detailing a net loss and a substantial drop in Adjusted EBITDA. The approval, which occurred on May 6, positions Tessie® to be marketed and sold exclusively in the United States by Orion's strategic partner, Zoetis, a major player in animal health. While the product is not anticipated to be available until mid-2027, this approval validates Orion's R&D capabilities and offers a clear future growth driver. Traders will monitor further updates on commercialization plans and sales forecasts.
At the time of this announcement, OEC was trading at $7.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $419.5M. The 52-week trading range was $4.35 to $12.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.